Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the frequency of continuous glucose monitoring (CGM) device use, factors associated with its use, and the relationship of CGM with diabetes outcomes (HbA1c, severe hypoglycemia [SH], and diabetic ketoacidosis [DKA]). RESEARCH DESIGN AND METHODS: Survey questions related to CGM device use 1 year after enrollment in the T1D Exchange clinic registry were completed by 17,317 participants. Participants were defined as CGM users if they indicated using real-time CGM during the prior 30 days. RESULTS: Nine percent of participants used CGM (6% of children <13 years old, 4% of adolescents 13 to <18 years, 6% of young adults 18 to <26 years, and 21% of adults ≥26 years). CGM use was more likely with higher education, higher household income, private health insurance, longer duration of diabetes, and use of insulin pump (P < 0.01 all factors). CGM use was associated with lower HbA1c in children (8.3% vs. 8.6%, P < 0.001) and adults (7.7% vs. 7.9%, P < 0.001). In adults, more frequent use of CGM (≥6 days/week) was associated with lower mean HbA1c. Only 27% of users downloaded data from their device at least once per month, and ≤15% of users reported downloading their device at least weekly. Among participants who used CGM at baseline, 41% had discontinued within 1 year. CONCLUSIONS: CGM use is uncommon but associated with lower HbA1c in some age-groups, especially when used more frequently. Factors associated with discontinuation and infrequent use of retrospective analysis of CGM data should be considered in developing next-generation devices and education on CGM use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such phenomena question the accuracy and credibility of CGM and make patients less reactive to alarms and less willing to retain them activated or even continue to use CGM [ 43 , 55 ].”
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Klonoff, D. C. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1231 · Cited by 724
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“occasional) use of CGM is associated with better glycemic control, as measured by HbA1c (5,8), leading to a practice guideline recommending CGM for adults who are able to use it at least 6 days a week (9).”
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490
The T1D exchange clinic registry
Beck, R. W., Tamborlane, W. V., Bergenstal, R. M., Miller, K. M., DuBose, S. N., Hall, C. A., & for the T1D Exchange Clinic Network (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1561 · Cited by 456
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1502 · Cited by 313
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 737
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543
Self-citationDhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Continuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Tanenbaum, M. L., Hanes, S. J., Miller, K. M., Naranjo, D., Bensen, R., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc16-1536 · Cited by 296
Self-citationAmerican Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 271
Farsani, S. F., Brodovicz, K., Soleymanlou, N., Marquard, J., Wissinger, E., & Maiese, B. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016587 · Cited by 251
“Several publications (for example, those based on the T1D Exchange Clinic Registry 11 22 29 33 36–38 ) relied on patient recall of past DKA events.”
BackgroundMethod7. Diabetes Technology: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s007 · Cited by 250
Wearable Continuous Glucose Monitoring Sensors: A Revolution in Diabetes Treatment
Cappon, G., Acciaroli, G., Vettoretti, M., Facchinetti, A., & Sparacino, G. (2017) · Electronics · doi:10.3390/electronics6030065 · Cited by 237
“On the other hand, in 2014 Abbott already launched in Europe the Freestyle Libre flash glucose monitoring system, which can be worn for 14 consecutive days (showing glucose levels when scanned by the user) with an accuracy of 11.4% MARD [49].”
BackgroundInfluentialDeSalvo, D. J., Miller, K. M., Hermann, J. M., Maahs, D. M., Hofer, S. E., Clements, M. A., Lilienthal, E., Sherr, J. L., Tauschmann, M., Holl, R. W., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12711 · Cited by 233
Self-citationComing of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 215
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 205
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationCharleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02498 · Cited by 196
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
An alternative sensor-based method for glucose monitoring in children and young people with diabetes
Edge, J., Acerini, C., Campbell, F., Hamilton-Shield, J., Moudiotis, C., Rahman, S., Randell, T., Smith, A., & Trevelyan, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311530 · Cited by 156
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Lawton, J., Blackburn, M., Allen, J., Campbell, F., Elleri, D., Leelarathna, L., Rankin, D., Tauschmann, M., Thabit, H., & Hovorka, R. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0239-1 · Cited by 174
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence
Cameron, F. J., Garvey, K., Hood, K. K., Acerini, C. L., & Codner, E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12702 · Cited by 155
Zaharieva, D. P., Turksoy, K., McGaugh, S. M., Pooni, R., Vienneau, T., Ly, T., & Riddell, M. C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0364 · Cited by 144
Park, W., Seo, H., Kim, J., Song, H., Song, H., Joo, B. J., Kim, E., Kim, E., Yae, C., Kim, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47123-9 · Cited by 167
“Inaddition,thesensorbodyisworn on the skin surface using the adhesive that is known to often induce skin irritations, such as hypersensitivity reactions and contact dermatitis 66,67 .”
Datye, K. A., Moore, D. J., Russell, W. E., & Jaser, S. S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0621-6 · Cited by 148
Consensus Statement on Inpatient Use of Continuous Glucose Monitoring
Wallia, A., Umpierrez, G. E., Rushakoff, R. J., Klonoff, D. C., Rubin, D. J., Hill Golden, S., Cook, C. B., Thompson, B., & Panel, T. D. C. G. M. I. T. H. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817706151 · Cited by 147
Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D., Denham, D. S., Atiee, G., Bode, B. W., Walters, S. J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0142 · Cited by 146
“A recent survey of individuals who initiated CGM in the T1D Exchange registry found that 41% of patients discontinued use during the first year.(11) Common reasons cited for discontinuation included discomfort wearing the sensor (42%), trouble inserting the sensor (33%), problems with adhesive securing sensor to skin…”
BackgroundSelf-citationBailey, T. S., Grunberger, G., Bode, B. W., Handelsman, Y., Hirsch, I. B., Jovanovič, L., Roberts, V. L., Rodbard, D., Tamborlane, W. V., & Walsh, J. S. A. (2016) · Endocrine Practice · doi:10.4158/ep151124.cs · Cited by 149
Self-citationImproving the clinical value and utility of CGM systems: issues and recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetologia · doi:10.1007/s00125-017-4463-4 · Cited by 148
Self-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
Tauschmann, M., Forlenza, G., Hood, K., Cardona‐Hernandez, R., Giani, E., Hendrieckx, C., DeSalvo, D. J., Laffel, L. M., Saboo, B., Wheeler, B. J., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13451 · Cited by 100
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135
Self-citationPettus, J., & Edelman, S. V. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663747 · Cited by 121
Šoupal, J., Petruželková, L., Flekač, M., Pelcl, T., Matoulek, M., Daňková, M., Škrha, J., Svačina, Š., & Prázný, M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0171 · Cited by 126
Role of continuous glucose monitoring for type 2 in diabetes management and research
Vigersky, R. A., & Shrivastav, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.007 · Cited by 126
Majidi, S., Ebekozien, O., Noor, N., Lyons, S. K., McDonough, R., Gandhi, K., Izquierdo, R., Demeterco-Berggren, C., Polsky, S., Basina, M., et al. (2021) · Clinical Diabetes · doi:10.2337/cd21-0028 · Cited by 118
Campbell, F. M., Murphy, N. P., Stewart, C., Biester, T., & Kordonouri, O. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12735 · Cited by 102
Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use
Tanenbaum, M. L., Adams, R. N., Hanes, S. J., Barley, R. C., Miller, K. M., Mulvaney, S. A., & Hood, K. K. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816688010 · Cited by 117
Self-citationDiabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress
Naranjo, D., Tanenbaum, M. L., Iturralde, E., & Hood, K. K. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816650900 · Cited by 110
“There are fewer international studies reporting on CGM usage; however, within T1D Exchange Clinic Registry in the United States, 21% of individuals above age 25 and 4-6% of individuals under 25 use CGM.(8,12) Overall, rates of CGM use across adult and youth participants is 7% of patients with T1D.”
BackgroundInfluentialThe Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities
Agarwal, S., Simmonds, I., & Myers, A. K. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01470-3 · Cited by 111
“[16, 21, 22] Although CGM utilization has been increasing since 2010, less than 38% of patients with T1D reported using CGM in the T1D Exchange as of 2018”
BackgroundAkinetic mutism: disconnection of frontal-subcortical circuits.
Mega, M. S., & COHENOUR, R. C. (1997) · PubMed · Cited by 108
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Yoo, J. H., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0257 · Cited by 107
A novel framework to evaluate innovation value proposition for smart product–service systems
Abdel-Basst, M., Mohamed, R. A., & Elhoseny, M. (2020) · Environmental Technology & Innovation · doi:10.1016/j.eti.2020.101036 · Cited by 105
Adherence to Glycemic Monitoring in Diabetes
Patton, S. R. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814567709 · Cited by 95
Racial disparities in treatment and outcomes of children with type 1 diabetes
Lipman, T. H., Smith, J. A., Patil, O., Willi, S. M., & Hawkes, C. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13139 · Cited by 103
Engler, R., Routh, T. L., & Lucisano, J. Y. (2018) · Clinical Diabetes · doi:10.2337/cd17-0053 · Cited by 84
Lee, J. M., Hirschfeld, E., & Wedding, J. (2016) · JAMA · doi:10.1001/jama.2016.1903 · Cited by 90
Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes
Slattery, D., & Choudhary, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0051 · Cited by 87
“39 However, with the advancement of CGM technology in recent years, newer generation devices have resulted in improved compliance, better tolerability, and patient satisfaction being much higher.”
Berg, A. K., Nørgaard, K., Thyssen, J. P., Zachariae, C., Hommel, E., Rytter, K., & Svensson, J. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0088 · Cited by 87
Little, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2682 · Cited by 86
Johnson, S. R., Holmes-Walker, D. J., Chee, M., Earnest, A., & Jones, T. W. (2022) · Diabetes Care · doi:10.2337/dc21-1666 · Cited by 86
Lee, J. M., Newman, M., Gebremariam, A., Choi, P. Y., Lewis, D. M., Nordgren, W., Costik, J., Wedding, J., West, B., Gilby, N. B., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0312 · Cited by 86
Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified
Anderson, J. E., Gavin, J. R., & Kruger, D. F. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0303 · Cited by 77
Increasing Hospitalizations for DKA: A Need for Prevention Programs
Vellanki, P., & Umpierrez, G. E. (2018) · Diabetes Care · doi:10.2337/dci18-0004 · Cited by 78
Psychological Reactions Associated With Continuous Glucose Monitoring in Youth
Patton, S. R., & Clements, M. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816638109 · Cited by 81
“Data from the Type 1 Diabetes (T1D) Exchange suggest that only 4-6% of children less than 18 years old use CGM compared to 21% of adults.(3) Moreover, among the reported CGM users, the same study found that youth reported a lower median number of days of CGM use compared to adults.”
BackgroundResultInfluentialJoseph, J. I. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820911919 · Cited by 81
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
“Unfortunately, their use may be intermittent for weekly sensor replacement [62].”
BackgroundBorot, S., Benhamou, P., Atlan, C., Bismuth, É., Bonnemaison, É., Catargi, B., Charpentier, G., Farret, A., Filhol, N., Franc, S., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.009 · Cited by 79
Vesco, A. T., Jedraszko, A. M., Garza, K. P., & Weissberg-Benchell, J. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818766381 · Cited by 70
Glycaemic Control in Youth and Young Adults: Challenges and Solutions
Khadilkar, A., & Oza, C. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s304347 · Cited by 79
“A study reports that youth with T1D rarely use continuous glucose monitoring (CGM) technology which is useful for improved glycaemic control and reduction of hypoglycaemia when used regularly.(34) Another study showed that approximately 65% of patients using an insulin pump miss >1 bolus doses of insulin per week.”
BackgroundGiani, E., Snelgrove, R., Volkening, L. K., & Laffel, L. M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816676280 · Cited by 71
“At 3 and 6 months, 15% and 20% of youth, respectively, had stopped using CGM.”
BackgroundResultInfluentialAng, E., Lee, Z. X., Moore, S., & Nana, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107559 · Cited by 67
Lado, J. J., & Lipman, T. H. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.01.002 · Cited by 71
Barriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 73
“Lower rates of insulin pump use are seen in males, racial and ethnic minorities, and those with no insurance or government insurance.(11,56,98,100) Additional concern comes from the possibility that these disparities in access may translate into differences in health outcomes, with some studies suggesting an associati…”
BackgroundVigersky, R. A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814565661 · Cited by 63
“The penetration of device use in the United States is relatively small, ranging from 4% in adolescents to 21% in adults and it is discontinued by 41% of patients within 1 year.(49) There are many possible reasons for this not the least Figure 1.”
BackgroundTechniques for Exercise Preparation and Management in Adults with Type 1 Diabetes
Pinsker, J. E., Kraus, A., Gianferante, D., Schoenberg, B. E., Singh, S., Ortiz, H., Dassau, E., & Kerr, D. E. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.04.010 · Cited by 72
Monitoring of Pediatric Type 1 Diabetes
Marks, B. E., & Wolfsdorf, J. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00128 · Cited by 71
“found that CGM use was more likely to be used among T1DX participants with higher education levels, higher household incomes, and private insurance (87).”
BackgroundForlenza, G. P., Buckingham, B., & Maahs, D. M. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.10.015 · Cited by 58
Self-citationImpact of Type 1 Diabetes Technology on Family Members/Significant Others of People With Diabetes
Barnard, K., Crabtree, V., Adolfsson, P., Davies, M., Kerr, D., Kraus, A., Gianferante, D., Bevilacqua, E., & Serbedzija, G. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816645365 · Cited by 61
“Discontinuation rates are high, however, at 41% of users having discontinued use by 1 year.(5) Currently, there is limited research on the impact of diabetes technologies on the lives of those people who live with someone with T1D and their role in helping them to support that person.”
BackgroundWhat End Users and Stakeholders Want From Automated Insulin Delivery Systems
Naranjo, D., Suttiratana, S. C., Iturralde, E., Barnard, K. D., Weissberg-Benchell, J., Laffel, L., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc17-0400 · Cited by 65
Aleppo, G., & Webb, K. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818813581 · Cited by 69
Self-citationWong, J. C., Neinstein, A. B., Spindler, M., & Adi, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0413 · Cited by 64
Self-citationPettus, J., Price, D. A., & Edelman, S. V. (2015) · Endocrine Practice · doi:10.4158/ep14520.or · Cited by 68
Chamberlain, J. J., Kalyani, R. R., Leal, S., Rhinehart, A. S., Shubrook, J. H., Skolnik, N., & Herman, W. H. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1259 · Cited by 61
Prevalence, Cost, and Burden of Diabetic Ketoacidosis
Virdi, N. S., Poon, Y., Abaniel, R. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0149 · Cited by 67
Self-citationNeinstein, A., Wong, J., Look, H., Arbiter, B., Quirk, K., McCanne, S., Sun, Y., Blum, M., & Adi, S. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv104 · Cited by 66
Self-citationNew Approaches to Providing Individualized Diabetes Care in the 21st Century
Powell, P., Corathers, S., Raymond, J., & Streisand, R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150421110316 · Cited by 60
“Similarly, use of personal CGMs is emerging in pediatric T1D patients particularly as accuracy and functionality of these devices continues to improve, and the additional information provided by these devices can assist with adjustments and fine-tuning of doses between clinic visits [81].”
BackgroundContinuous Glucose Monitoring and Global Reimbursement: An Update
Graham, C. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0096 · Cited by 62
Improved A1C Levels in Type 1 Diabetes with Smartphone App Use
Ryan, E. A., Holland, J., Stroulia, E., Bazelli, B., Babwik, S. A., Li, H., Senior, P., & Greiner, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.06.001 · Cited by 63
Burnside, M. J., Williman, J. A., Davies, H. M., Jefferies, C., Paul, R. G., Wheeler, B. J., Wiltshire, E. J., Anderson, Y. C., & de Bock, M. I. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100644 · Cited by 63
“Cost-effective analyses also favour rtCGM over self-monitoring of blood glucose (SMBG) and isCGM.”
InfluentialRoutine use of continuous glucose monitoring in 10 501 people with diabetes mellitus
Battelino, T., Liabat, S., Veeze, H. J., Castañeda, J., Arrieta, A., & Cohen, O. (2015) · Diabetic Medicine · doi:10.1111/dme.12825 · Cited by 57
Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions
Castle, J. R., & Jacobs, P. G. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816631569 · Cited by 56
Deiss, D., Szadkowska, A., Gordon, D., Mallipedhi, A., Schütz-Fuhrmann, I., Aguilera, E., Ringsell, C., Block, C. E. M. D., & Irace, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0397 · Cited by 62
Chamberlain, J. J., Doyle-Delgado, K., Peterson, L., & SKOLNIK, N. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1638 · Cited by 60
Friedman, J. G., Cardona, Z., Szmuilowicz, E. D., & Aleppo, G. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s374663 · Cited by 60
“A 2014 survey of over 17,000 participants who had T1D and had used CGM at baseline noted that 41% had discontinued CGM within 1 year, and the top cited reasons were discomfort when wearing CGM, problems with inserting the CGM sensor, and problems with adhesive holding the sensor on the skin.(45) Adhesion can be improv…”
BackgroundSelf-citationCook, A. J., DuBose, S. N., Foster, N., Smith, E. L., Wu, M., Margiotta, G., Rickels, M. R., Speight, J., de Zoysa, N., & Amiel, S. A. (2019) · Diabetes Care · doi:10.2337/dc19-0002 · Cited by 52
Self-citationRigo, R. S., Levin, L. E., Belsito, D. V., Garzon, M. C., Gandica, R., & Williams, K. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820918894 · Cited by 58
Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?
Barnard, K. D., Pinsker, J. E., Oliver, N., Astle, A., Dassau, E., & Kerr, D. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0316 · Cited by 52
Barriers to Type 1 Diabetes Adherence in Adolescents
Azar, S., Jaoude, N. M. A., Kędzia, A. W., & Niechciał, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195669 · Cited by 54
“In addition, even the new medical technologies with tendencies to facilitate and enhance treatment, like continuous glucose monitoring (CGM), still challenge adherence to therapy in teenagers [13].”
BackgroundBarnard, K. D., Hood, K. K., Weissberg-Benchell, J., Aldred, C., Oliver, N., & Laffel, L. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0305 · Cited by 48
Forlenza, G. P., Argento, N. B., & Laffel, L. M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0034 · Cited by 44
Messaaoui, A., Tenoutasse, S., & Crenier, L. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0339 · Cited by 51
Tanenbaum, M. L., Adams, R. N., Lanning, M. S., Hanes, S. J., Agustin, B. I., Naranjo, D., & Hood, K. K. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818786486 · Cited by 50
Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring
Lundholm, M. D., Emanuele, M. A., Ashraf, A., & Nadeem, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107585 · Cited by 54
Klonoff, D. C., & Kerr, D. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817723260 · Cited by 47
Choudhary, P., & Amiel, S. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4566-6 · Cited by 52
Metadata
- Authors
- Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., Kleis, L., Chase, H. P., DuBose, S. N., Miller, K. M., Beck, R. W., Adi, S., & for the T1D Exchange Clinic Network
- Affiliations
- University of California, San Francisco (US)
- Jaeb Center for Health Research (US)
- University of Colorado Denver (US)
- Park Nicollet Health Services (US)
- Oregon Health & Science University (US)
- University of Southern California (US)
- Atlanta Diabetes Associates (US)
- Northwestern University (US)
- University of Washington (US)
- Spectrum Health (US)
- Corresponding author
- Miller, Kellee M.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-10
- Volume
- 37
- Issue
- 10
- Pages
- 2702-2709
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4392936
- OpenAlex
- W2136450455
- Semantic Scholar
- a3013d7ae63769a7d02f5f5ea02fd388f34dfe01
- Cited by
- 318
- References
- 19
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 27 · 2020: 33 · 2019: 38 · 2018: 45 · 2017: 35 · 2016: 32 · 2015: 29 · 2014: 2
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5k12dk094726-05, UL1TR000142)
- National Institute of Diabetes and Digestive and Kidney Diseases (K12-DK094726)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- continuous glucose monitoring, type 1 diabetes, HbA1c, severe hypoglycemia, diabetic ketoacidosis, insulin pump, socioeconomic factors, age differences
- MeSH terms
- Adolescent, Adult, Blood Glucose, Child, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Patient Education as Topic, Registries, Retrospective Studies, Risk Factors, Blood Glucose Self-Monitoring, Incidence, Diabetic Ketoacidosis, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.